In colon cancer cells, silencing of ST6GAL1 increased the anti-cancer effect of the EGFR inhibitor gefitinib, whereas ST6GAL1 overexpression decreased the cytotoxic effect of gefitinib [108]. The gene discussed is ST6GAL1; the disease is malignant colon neoplasm.